Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174731 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,133
- Enrollment target
NCT02174731 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,133 participants.
The verdict
NCT02174731, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,133 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
Interventions
- DRUG Epoetin alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,133 participants |
| Start Date | 2014-07-01 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174731
The ClinicalTrials.gov registry entry for NCT02174731 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin alfa is the first listed.
NCT02174731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02174731 about?
NCT02174731 is a clinical study titled "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.". The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
What is the current status of trial NCT02174731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,133 participants. The study started on 2014-07-01. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02174731?
The interventions under investigation include: Epoetin alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02174731?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.